Patterns of publicly funded naltrexone use among patients diagnosed with alcohol use disorder in Ontario

Worldwide, alcohol use disorders (AUD) are common mental health diagnoses, playing a significant role in increased injuries, health problems, and deaths in Canada each year. Naltrexone, a long-acting nonselective opioid-receptor antagonist, is a primary medication in Ontario for treating AUD. Despite its established safety and efficacy, studies conducted outside Ontario suggest low retention rates for naltrexone.

This study investigated the duration of naltrexone use among individuals in Ontario who initiated therapy for AUD, and if the healthcare setting where naltrexone was prescribed had an impact on the time to therapy discontinuation.

Access the full article:

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.